Symptoms and General Pathology

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Nervous System Diseases

Neoplasms

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Behaviors and Mental Disorders

Syndrome

Apnea

Sleep Apnea Syndromes

Sleep Apnea, Obstructive

Oropharyngeal Neoplasms

Respiration Disorders

Respiratory Tract Diseases

Parasomnias

Sleep Disorders, Intrinsic

Dyssomnias

Sleep Wake Disorders

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by surgery

Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by radio-chemotherapy

Surgery

Radio- chemotherapy

Catherine GEINDRE

The level of knowledge about the consequences of oropharyngeal cancer treatment on sleep quality remains poor. Because of a high level of risk of developing an Obstructive Sleep Apnea Syndrome (OSAS), an accurate evaluation of the prevalence, of the risk factors and of the impact on quality of life is important in order to propose preventive and therapeutic solutions to these patients.

Obstructive sleep apnea syndrome (OSAS) remains poorly documented in head and neck cancer cancer population, who have a higher risk than the general population. OSAS is a risk factor for quality of life impairment and cardiovascular morbidity and mortality.

This study proposes to carry out an OSAS prevalence study among a locally advanced head and neck cancer population, already treated and to compare the consequences of current therapeutic options in sleep quality.The primary research objective will be a prevalence determination in a locally advanced stages treated population of oropharyngeal cancer. Secondary objectives will be the comparison of the prevalence between the surgical group and the radio-chemotherapy group, the research of predictive factors of presenting an OSAS and the precision of the impact on quality of life.

Obstructive Sleep Apnea Syndrome After Oropharyngeal Cancer Treatment

For an IAH \<10: no Obstructive Sleep Apnea Syndrome (OSAS) For an IAH\>30: severe OSAS is diagnosed

Assistance Publique Hopitaux De Marseille

Blood and Lymph Conditions

Heart and Blood Diseases

Rare Diseases

Polycythemia Vera

Polycythemia

Disease Progression

Thrombocytosis

Thrombocythemia, Essential

Signs and Symptoms, Respiratory

Hematologic Diseases

Bone Marrow Neoplasms

Hematologic Neoplasms

Bone Marrow Diseases

Myeloproliferative Disorders

Blood Platelet Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Hemorrhagic Disorders

Essential Thrombocythemia

Chronic Myeloproliferative Disorders

Patients not diagnosed with OSA undergo observation for 6 months.

Patients diagnosed with OSA and prescribed a CPAP machine for treatment receive continuous treatment with CPAP for 6 months.

Continuous Positive Airway Pressure

Patient Observation

Questionnaire Administration

Krishna Sundar

This early phase I trial studies how well the use of a continuous positive airway pressure (CPAP) machine works in treating obstructive sleep apnea in patients with polycythemia vera or essential thrombocythemia. Obstructive sleep apnea is a condition where a person stops breathing during sleep, and is estimated to affect 30 to 50 percent of patients with polycythemia vera or essential thrombocythemia. A patient with obstructive sleep apnea typically snores, has disrupted sleep, experiences morning headaches, and has daytime sleepiness. Patients diagnosed with obstructive sleep apnea are typically treated with a device called CPAP. The CPAP provides pressurized air that keeps upper air passages open during sleep and may prevent them from narrowing or collapsing as occurs during snoring or sleep apnea.

PRIMARY OBJECTIVES:

I. To understand effects of continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA) on the course of polycythemia vera/essential thrombocythemia (PV/ET).

EXPLORATORY OBJECTIVES:

I. To estimate prevalence of OSA in patients with myeloproliferative neoplasms. II. To understand effects of CPAP for sleep apnea on the course of myeloproliferative neoplasms (MPNs).

III. To correlate OSA severity with thrombotic and inflammatory marker values in patients with PV/ET at baseline.

OUTLINE: Patients are assigned to 1 of 2 cohorts.

COHORT I (OBSERVATIONAL COHORT): Patients not diagnosed with OSA undergo observation for 6 months.

COHORT II (TREATMENT COHORT): Patients diagnosed with OSA and prescribed a CPAP machine for treatment receive continuous treatment with CPAP for 6 months.

CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia

Modulation of Morbidity and Disease Progression in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Patients With Obstructive Sleep Apnea (OSA) by CPAP

Assessed by Snoring, Tiredness, Observed Apnea, Blood Pressure, Body Mass Index, Age, Neck Circumference and Gender (STOP-BANG) questionnaire. The proportion of patients whose results indicate a diagnosis of OSA will be calculated. All patients with a diagnosis of OSA, regardless of whether they are enrolled to the treatment component of the study, will be counted towards the assessment of prevalence. An assessment of normality will be made prior to statistical testing. Paired t tests will be used to analyze endpoints that are sufficiently Gaussian in distribution. Paired Wilcoxon tests will be used to analyze variables that are highly skewed or otherwise non-Gaussian in distribution.

The endpoints will be summarized by mean, median, range, standard deviation, interquartile range and boxplots. Scatterplots will be used to show bivariate associations. An assessment of normality will be made prior to statistical testing. Paired t tests will be used to analyze endpoints that are sufficiently Gaussian in distribution. Paired Wilcoxon tests will be used to analyze variables that are highly skewed or otherwise non-Gaussian in distribution.

Will be measured in blood samples taken from all patients. OSA-related adverse events reported in the Treatment Cohort at these timepoints will be correlated with these marker levels. Pearson or Spearman correlation will be used to assess correlation between thrombo-inflammatory markers and oximetric abnormalities.

Will be tested at the two-sided 0.025 significance level to provide overall control of the type I error for the co-primary endpoints at 0.05. The endpoints will be summarized by mean, median, range, standard deviation, interquartile range and boxplots. Scatterplots will be used to show bivariate associations. An assessment of normality will be made prior to statistical testing. Paired t tests will be used to analyze endpoints that are sufficiently Gaussian in distribution. Paired Wilcoxon tests will be used to analyze variables that are highly skewed or otherwise non-Gaussian in distribution.

National Cancer Institute (NCI)

University of Utah

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Obstructive Sleep Apnea Syndrome After Oropharyngeal Cancer Treatment	NCT02881723	Obstructive Sle... Oropharyngeal C...	Surgery Radio- chemothe...	18 Years -	Assistance Publique Hopitaux De Marseille
CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia	NCT03972943	CALR Gene Mutat... Essential Throm... JAK2 Gene Mutat... MPL Gene Mutati... Obstructive Sle... Polycythemia Ve...	Continuous Posi... Patient Observa... Questionnaire A...	30 Years - 85 Years	University of Utah
CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia	NCT03972943	CALR Gene Mutat... Essential Throm... JAK2 Gene Mutat... MPL Gene Mutati... Obstructive Sle... Polycythemia Ve...	Continuous Posi... Patient Observa... Questionnaire A...	30 Years - 85 Years	University of Utah
Obstructive Sleep Apnea Syndrome After Oropharyngeal Cancer Treatment	NCT02881723	Obstructive Sle... Oropharyngeal C...	Surgery Radio- chemothe...	18 Years -	Assistance Publique Hopitaux De Marseille
CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia	NCT03972943	CALR Gene Mutat... Essential Throm... JAK2 Gene Mutat... MPL Gene Mutati... Obstructive Sle... Polycythemia Ve...	Continuous Posi... Patient Observa... Questionnaire A...	30 Years - 85 Years	University of Utah

Spots Global Cancer Trial Database for obstructive sleep apnea syndrome